The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
The Clinical Plasma Proteome: A Survey of Clinical Assays for Proteins in Plasma and Serum
Abstract
An analysis of all US Food and Drug Administration (FDA) approvals for protein-based assays through 2008 reveals 109 unique protein targets in plasma or serum, as well as 62 additional tests for peptides, protein posttranslational modifications, protein complexes, autoantibodies against endogenous proteins, and blood cell proteins. A further 96 unique protein targets are assayed in plasma by laboratory-developed tests available for clinical use in the US, yielding a total of 205 proteins that include products of approximately 211 genes (excluding immunoglobulins). These tests provide quantitative measurements for approximately 1% of the human protein gene products, defining a practical clinical plasma proteome. The rate of introduction of new protein analytes has remained essentially flat over the past 15 years, averaging 1.5 new proteins per year (median of 1 per year). This rate falls far short of that needed to support projected medical needs and indicates serious deficiencies in the protein biomarker pipeline, from which no proteomics-discovered analytes have yet emerged.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Anderson, N. L., & Anderson, N. G. (2002) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r200007-mcp200 · Cited by 4,414
Self-citationImmunoassay of endogenous plasma insulin in man
Yalow, R. S., & Berson, S. A. (1960) · Journal of Clinical Investigation · doi:10.1172/jci104130 · Cited by 3,041
Tietz Textbook of Clinical Chemistry
(1999) · Archives of Pathology and Laboratory Medicine · doi:10.5858/123.7.646b · Cited by 2,495
Protein biomarker discovery and validation: the long and uncertain path to clinical utility
Rifai, N., Gillette, M. A., & Carr, S. A. (2006) · Nature Biotechnology · doi:10.1038/nbt1235 · Cited by 1,867
Addona, T. A., Abbatiello, S. E., Schilling, B., Skates, S. J., Mani, D. R., Bunk, D. M., Spiegelman, C. H., Zimmerman, L. J., Ham, A.-J. L., Keshishian, H., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1546 · Cited by 1,037
Self-citationOmenn, G. S., States, D. J., Adamski, M., Blackwell, T. W., Menon, R., Hermjakob, H., Apweiler, R., Haab, B. B., Simpson, R. J., Eddes, J. S., et al. (2005) · PROTEOMICS · doi:10.1002/pmic.200500358 · Cited by 787
Distinguishing protein-coding and noncoding genes in the human genome
Clamp, M., Fry, B., Kamal, M., Xie, X., Cuff, J., Lin, M. F., Kellis, M., Lindblad-Toh, K., & Lander, E. S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709013104 · Cited by 624
The fundamental flaws of immunoassays and potential solutions using tandem mass spectrometry
Hoofnagle, A. N., & Wener, M. H. (2009) · Journal of Immunological Methods · doi:10.1016/j.jim.2009.06.003 · Cited by 561
Bias as a threat to the validity of cancer molecular-marker research
Ransohoff, D. F. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1550 · Cited by 487
IMMUNOASSAY OF ENDOGENOUS PLASMA INSULIN IN MAN
YALOW, R. S., & BERSON, S. A. (1996) · Obesity Research · doi:10.1002/j.1550-8528.1996.tb00274.x · Cited by 460
Hortin, G. L., Sviridov, D., & Anderson, N. L. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.108175 · Cited by 269
Self-citationSkates, S. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.955 · Cited by 256
Characterization of the human blood plasma proteome
Shen, Y., Kim, J., Strittmatter, E. F., Jacobs, J. M., Camp, D. G., Fang, R., Tolié, N., Moore, R. J., & Smith, R. D. (2005) · PROTEOMICS · doi:10.1002/pmic.200401246 · Cited by 225
A Human Proteome Detection and Quantitation Project
Anderson, N. L., Anderson, N. G., Pearson, T. W., Borchers, C. H., Paulovich, A. G., Patterson, S. D., Gillette, M., Aebersold, R., & Carr, S. A. (2009) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r800015-mcp200 · Cited by 200
Self-citationA high confidence, manually validated human blood plasma protein reference set
Schenk, S., Schoenhals, G. J., de Souza, G., & Mann, M. (2008) · BMC Medical Genomics · doi:10.1186/1755-8794-1-41 · Cited by 181
Circulating nucleic acids in plasma/serum
Tsang, J. C. H., & Dennis Lo, Y. M. (2007) · Pathology · doi:10.1080/00313020701230831 · Cited by 181
Protein Quantitation through Targeted Mass Spectrometry: The Way Out of Biomarker Purgatory?
Carr, S. A., & Anderson, L. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.114686 · Cited by 141
The Roles of Multiple Proteomic Platforms in a Pipeline for New Diagnostics
Anderson, N. L. (2005) · Molecular & Cellular Proteomics · doi:10.1074/mcp.i500001-mcp200 · Cited by 120
Self-citation
Cited by
Protein Analysis by Shotgun/Bottom-up Proteomics
Zhang, Y., Fonslow, B. R., Shan, B., Baek, M.-C., & Yates, J. R. (2013) · Chemical Reviews · doi:10.1021/cr3003533 · Cited by 1,491
Biomedical research: increasing value, reducing waste.
Macleod, M. R., Michie, S., Roberts, I., Dirnagl, U., Chalmers, I., Ioannidis, J. P. A., Salman, R. A.-S., Chan, A.-W., & Glasziou, P. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62329-6 · Cited by 1,003
Revisiting biomarker discovery by plasma proteomics
Geyer, P. E., Holdt, L. M., Teupser, D., & Mann, M. (2017) · Molecular Systems Biology · doi:10.15252/msb.20156297 · Cited by 917
Plasma Proteome Profiling to Assess Human Health and Disease
Geyer, P. E., Kulak, N. A., Pichler, G., Holdt, L. M., Teupser, D., & Mann, M. (2016) · Cell Systems · doi:10.1016/j.cels.2016.02.015 · Cited by 734
“5 per year in the 15 years before 2010 (Anderson, 2010)— and this has generally been done by immunoassay-based technologies, such as prostate-specific antigen, one of the best known biomarkers in medicine (Vihko et al.”
BackgroundMethodInfluentialHigh-Resolution Native Mass Spectrometry
Tamara, S., den Boer, M. A., & Heck, A. J. R. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00212 · Cited by 511
Metadata
- Authors
- Anderson, N. L.
- Venue
- Clinical Chemistry
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-02-01
- Volume
- 56
- Issue
- 2
- Pages
- 177-185
- ISSN
- 0009-9147 (ISSN-L)
- 1530-8561
- OpenAlex
- W2160061958
- Cited by
- 562
- References
- 18
- FWCI
- 14.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.